http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
무선 센서네트워크에서 상황인식기반 실시간 감시시스템 개발
조경진(Kyoung-Jin Jo),김희대(Hee-Dae Kim),이현조(Hyun-Jo Lee),심춘보(Chun-Bo Sim),장재우(Jae-Woo Chang) 한국콘텐츠학회 2011 한국콘텐츠학회논문지 Vol.11 No.4
최근 유무선 통신 기술의 발전 및 모바일 정보기기의 보편화에 힘입어, 시간과 장소에 제약 없이 서비스를 제공할 수 있는 유비쿼터스 컴퓨팅(Ubiquitous computing)기술이 각광받고 있다. 이에 따라, 무선 센서네트워크(Wireless Sensor Network: WSN) 기술과 상황인식(Context-awareness) 기술에 대한 관심이 크게 고조 되고 있으며, WSN과 상황인식을 접목하여 다양한 분야에서 활용할 수 있는 응용시스템의 개발이 활발하다. 하지만 기존 상황인식 기술을 WSN에 적용할 경우, 첫째, 불필요한 데이터를 전송하여 에너지효율성을 저하시키는 단점이 존재한다. 둘째, 새로운 응용 서비스를 구현할 경우, 특정 응용에 의존적이기 때문에, 새로운 상황인식 모듈을 구현해야 하는 문제점이 있다. 이를 위해 본 연구에서는 무선 센서 네트워크에서 상황인식에 근거한 새로운 실시간 감시시스템을 제안한다. 제안하는 시스템은 센서노드에서 상황인식을 수행하여 불필요한 데이터 전송을 줄여 에너지 효율성을 높이고, 모듈화를 통해 새로운 상황인식 기능을 지원할 수 있는 확장성을 지닌다. Due to recent development in wireless communication technologies and mobile information devices, the services on ubiquitous computing technology without time and place restriction have been spotlighted. Moreover, the interest of the Wireless Sensor Networks (WSNs) and context-awareness technologies have largely been escalating and their technologies utilization is active in the various applications such as healthcare, farm management and so on. However, the direct adaption of the existing context-awareness technique to the WSN technology has several drawbacks as follows. First, such systems waste precious energy of sensor nodes, due to unnecessary data transmissions. Secondly, since the existing work was designed to support only specific applications, it is required to implement a new context-awareness application for a specific purpose. Therefore, we, in this paper, propose a new real-time monitoring system based on context-awareness in WSNs. Our system not only enhances energy efficiency by reducing data transmissions by doing context-awareness on a sensor node, but also is scalable in terms of supporting new context-awareness functionalities through modularization.
다양한 가공방법으로 제조한 반건조 숭어의 영양학적 및 미생물학적 특성
조희근(Hee Geun Jo),김민주(Min Ju Kim),문보영(Bo Yeong Moon),신용식(Yong Sik Sin),이경선(Kyoung Seon Lee),정선희(Sun Hee Cheong) 한국식품영양과학회 2021 식품산업과 영양 Vol.26 No.1
본 연구에서는 제조 방법을 달리하여 제조한 건정 숭어 4개 군(물-냉풍, 물-진공, 황칠-냉풍 및 황칠-진공)의 영양학적 특성, 지질산패 및 미생물학적 특성을 평가하였다. 염도는 건정 숭어 군들 간에 유의적인 차이를 보이지 않았으나, 수분활성도의 경우 물-냉풍 및 물-진공 군이 황칠-냉풍 및 황칠-진공건조 군에 비해 유의적으로 낮은 수분활성도를 보였다. 지질산패의 척도인 과산화물가, 산가 및 TBARS 값은 모두 유사한 양상을 보였는데, 특히 황칠-냉풍 군이 가장 낮은 과산화물가 및 TBARS 값을 보였다. 총 균수의 경우도 지질산패 지표들과 유사하게 황칠-냉풍 군이 가장 낮은 총 균수를 나타냈다. 반면, 본 연구에서 모든 건정 숭어 시료 내에서 식중독의 원인균인 대장균, 장염비브리오균, 황색포도상구균은 검출되지 않았다. 이상의 연구결과를 종합해볼 때, 건정 숭어의 지질산패 및 미생물학적 제어를 위해서는 황칠-냉풍 처리 공정이 가장 효과적인 것으로 사료된다.
Park, Yeon Hee,Kim, Tae-Yong,Kim, Gun Min,Kang, Seok Yun,Park, In Hae,Kim, Jee Hyun,Lee, Kyoung Eun,Ahn, Hee Kyung,Lee, Moon Hee,Kim, Hee-Jun,Kim, Han Jo,Lee, Jong In,Koh, Su-Jin,Kim, Ji-Yeon,Lee, Kyu ELSEVIER 2019 LANCET ONCOLOGY Vol.20 No.12
<P><B>Summary</B></P> <P><B>Background</B></P> <P>Endocrine treatment is recommended by clinical guidelines as the preferred treatment option for premenopausal as well as postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. In real-world clinical practice, however, a substantial number of patients are treated with chemotherapy. We aimed to compare the clinical antitumour activity and safety of palbociclib plus endocrine therapy with that of capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.</P> <P><B>Methods</B></P> <P>This multicentre, open-label, randomised, phase 2 study was done in 14 academic institutions in South Korea. Premenopausal women aged 19 years or older with hormone receptor-positive, HER2-negative breast cancer that had relapsed or progressed during previous tamoxifen therapy and with an Eastern Cooperative Oncology Group performance status of 0–2 were included. One line of previous chemotherapy for metastatic breast cancer was allowed. Patients were randomly assigned, using a random permuted block design (with a block size of two), to receive palbociclib plus combination endocrine therapy (oral exemestane 25 mg per day for 28 days and oral palbociclib 125 mg per day for 21 days every 4 weeks plus leuprolide 3·75 mg subcutaneously every 4 weeks) or chemotherapy (oral capecitabine 1250 mg/m<SUP>2</SUP> twice daily for 2 weeks every 3 weeks). Randomisation was stratified by previous chemotherapy for metastatic breast cancer and visceral metastasis. The primary endpoint was progression-free survival. All analyses were done in a modified intention-to-treat population that excluded patients who did not receive study medication. This study is registered with ClinicalTrials.gov, NCT02592746, and is ongoing for follow-up of overall survival.</P> <P><B>Findings</B></P> <P>Between June 15, 2016, and Dec 10, 2018, 189 patients were enrolled, of whom 184 were randomly assigned to the palbociclib plus endocrine therapy group (n=92) or the capecitabine group (n=92). Six patients in the capecitabine group withdrew from the study before drug administration; therefore, 92 patients in the palbociclib plus endocrine therapy group and 86 patients in the capecitabine group were included in the modified intention-to-treat analyses. 46 (50%) of 92 patients in the palbociclib plus endocrine therapy group and 45 (51%) of 92 in the capecitabine group were treatment naive for metastatic breast cancer. During a median follow-up of 17 months (IQR 9–22), median progression-free survival was 20·1 months (95% CI 14·2–21·8) in the palbociclib plus endocrine therapy group versus 14·4 months (12·1–17·0) in the capecitabine group (hazard ratio 0·659 [95% CI 0·437–0·994], one-sided log-rank p=0·0235). Treatment-related grade 3 or worse neutropenia was more common in the palbociclib plus endocrine therapy group than in the capecitabine group (69 [75%] of 92 <I>vs</I> 14 [16%] of 86 patients). 2 (2%) patients in the palbociclib plus endocrine therapy group and 15 (17%) patients in the capecitabine group had treatment-related serious adverse events. No treatment-related deaths occurred.</P> <P><B>Interpretation</B></P> <P>Exemestane plus palbociclib with ovarian function suppression showed clinical benefit compared with capecitabine in terms of improved progression-free survival in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Palbociclib plus exemestane with ovarian suppression is an active treatment option in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer who have been pretreated with tamoxifen.</P> <P><B>Funding</B></P> <P>Pfizer, Shinpoong, and Daewoong Korea and Takeda.</P>
Jee-Hwa Hong,Eun-Jo Shim,Moo-Kyoung Yoon,Eun-Hee Soh 한국육종학회 2015 한국육종학회 심포지엄 Vol.2015 No.07
Blueberry (Vaccinium spp.) is a member of the Ericaceae and eleven varieties have been registered at the Korea Seed & Variety Service for Plant Variety Protection (PVP). This study was to develop simple sequence repeat (SSR) markers next generation sequencing (NGS) analysis and to analysis genetic relationship of blueberry 31 varieties. Highbush blueberry ‘Camellia’ and rabbiteye blueberry ‘Alapaha’ varieties were used as sequencing materials. Out of total 987 SSR primers detected between ‘Camellia’ and ‘Alapaha’, 148 SSR primers were initially applied to select SSR markers for identification of blueberry varieties. Fourteen SSR markers showed polymorphism between 8 varieties. Seven SSR markers showed reproducibility and clear peak among 14 SSR markers. Genetic relationships of 31 blueberry varieties were analyzed and identified using 7 SSR markers. A total of 30 polymorphic SSR alleles were obtained and two to seven alleles were detected for each locus with an average of 4.3 alleles per locus. Average polymorphism information content was 0.556, ranging from 0.374 to 0.714. Genetic distance of clusters ranged from 0.38 to 0.93 by unweighted pair-group method with arithmetical average based on Jaccard’s distance coefficients. These newly developed SSR markers indicate usefulness for variety identification related to seed dispute and distinctness, uniformity and stability (DUS) test for blueberry.
Expression profiles of HERV-K Env protein in normal and cancerous tissues
Jo, Jin-Ok,Kang, Yun-Jeong,Ock, Mee Sun,Song, Kyoung Seob,Jeong, Moon-Jin,Jeong, Soon-Jeong,Choi, Yung Hyun,Ko, Eun-Ji,Leem, Sun-Hee,Kim, Suhkmann,Kim, Heui-Soo,Cha, Hee-Jae Springer-Verlag 2016 Genes & Genomics Vol.38 No.1
<P>Human endogenous retroviruses (HERVs) have been proposed as etiological cofactors in chronic diseases such as cancer, autoimmunity and neurological disease. HERV RNA expression is also increased in several autoimmune diseases and cancers. However, only a few studies have analyzed the expression levels of HERV-derived proteins in normal and diseased tissues. Here, we investigated the expression profiles of HERV-K Env protein, which is the most well-known pathogen, from normal and cancer tissue microarray. Normal and cancer tissue microarray slides containing 59 normal or 60 tumor surgical specimens, respectively were immunostained with mouse monoclonal antibody to HERV-K and staining intensity was scored. The expression of HERV-K Env protein is generally low in normal tissues but high in specific tissues including bronchus submucosal gland, salivary gland acini, pancreas acini, testis seminiferous tubule, uterine cervix epithelium, ovary stroma, skin epidermis, and heart. The expression of HERV-K Env protein in tumors was usually higher than normal tissues and specifically high in breast, liver, stomach, prostate, and ovarian cancer. This study provides protein expression profiles of HERV-K Env protein in human normal and cancer tissues and provides a good reference for further studies on the expression patterns and roles of HERV-K Env protein in normal organs and various cancers. Further studies with specific organs or cancers and a statistically significant numbers of samples are necessary.</P>